Purchase Order 75N92E19P00042

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $17,735.76 on December 21, 2018, with completion by December 25, 2019. The order is a firm fixed price acquisition with no set-aside. Work is performed at Bethesda, Maryland. The purchase order procures DNA and RNA sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product lines serving federal health and research agencies.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $9,715.00 on October 19, 2017, with an ultimate completion date of November 18, 2017. Work is performed in North Bethesda, Maryland. The order is firm fixed price with no set-aside. The source does not specify the technical scope of materials or services procured under this purchase order.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. valued at $14,425.00 on January 31, 2018, with ultimate completion on February 1, 2019. Work is performed at North Bethesda, Maryland. The order is a firm fixed price commercial acquisition with no set-aside designation. Specific line items and scope details are not provided in the source material.</p>

<p>The National Human Genome Research Institute issued a $64,614.22 delivery order to Illumina, Inc. on September 13, 2017, for supplies. The order is firm fixed price with an ultimate completion date of October 12, 2017. Place of performance is North Bethesda, MD.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $6,708.01 on July 13, 2018, with an ultimate completion date of August 12, 2018. Performance occurs in North Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific line items or procurement scope are not detailed in the award record.</p>

<p>The National Human Genome Research Institute issued a $24,926.45 delivery order to Illumina, Inc. on September 19, 2019, under a firm fixed-price structure.</p> <p>Place of performance is Bethesda, MD. The order was due for completion on September 2, 2020. No set-aside was applied to this delivery order.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $15,314.69 on August 23, 2017, with an ultimate completion date of September 22, 2017. Work is performed in North Bethesda, Maryland. The order covers sequencing reagents and consumables under firm fixed price terms. No set-aside applied.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $10,517.76 on March 28, 2019, with completion due April 26, 2019. Place of performance is San Diego, California. The order is firm fixed price with no set-aside category. Specific procurement details regarding the items or services ordered are not provided in the source.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. for $15,314.69 on July 31, 2018, with final completion by August 29, 2018. The order is firm fixed price with no set-aside. Performance occurs in Bethesda, Maryland. The purchase order procures sequencing reagents, consumables, or related bioinformatics products from Illumina's core portfolio of DNA and RNA sequencing supplies and software.</p>

<p>The National Human Genome Research Institute awarded a purchase order to Illumina, Inc. valued at $19,792.44 on August 15, 2018, for DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software. Performance is at North Bethesda, Maryland, with an ultimate completion date of September 14, 2018. The order carries firm fixed price terms and no set-aside designation.</p>